Plus Therapeutics Inc

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Plus Therapeutics advances trials, secures funding, and expands diagnostics

Plus Therapeutics demonstrates strong financial and operational progress with successful funding, grants, and trial advancements.
Strategic additions to the management team and diagnostic capabilities enhance the company's expertise and market positioning.
Challenges in financial management, regulatory processes, and dosing strategies require careful navigation for sustained growth and success.
Opportunities lie in FDA feedback, commercial launches, collaborations, and positive trial outcomes for future growth and market impact.

Plus Therapeutics Inc (PSTV) reports clinical progress amidst financial challenges

Plus Therapeutics Inc (PSTV) made significant clinical advancements in Q2 2024, while facing financial challenges. The company's strengths include positive trial results and supportive conference data, with opportunities for growth through expanded capabilities and funding access.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biocept

Biocept Inc (NASDAQ:BIOC) and Plus Therapeutics Inc have announced a comprehensive laboratory services agreement for Plus Therapeutics' ReSPECT-LM trial for the treatment of cancer in the membranes that surround the brain and spinal cord.  Under the multi-year agreement, Biocept's cerebrospinal fluid (CSF) assay CNSide1 will be employed in Plus Therapeutics' ReSPECT-LM Phase 1/2a dose-escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of patients with leptomeningeal metastases (LM).

Biocept enters into comprehensive laboratory services agreement with Plus Therapeutics for cancer trial

Biocept's CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system

Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial

Rhenium-186 NanoLiposome (186RNL) Targeted Radiotherapeutic successfully delivered without dose limiting toxicities in initial cohort

Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial

Data validates continued high radiation absorbed of 186 RNL in escalating doses to treat glioblastoma, maintaining safety and limiting brain and whole-body exposure

Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting

AUSTIN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present virtually at the 2022 H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

Plus Therapeutics to Present Virtually at the 2022 HC Wainwright Global Investment Conference

Creatd Inc

LiveOne

US crude oil futures traded higher this morning on Friday. Investors, meanwhile, focused on some notable insider trades.

3 Stocks Under $1 Insiders Are Aggressively Buying

AUSTIN, Texas, April 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the 2022 Q2 Investor Summit on Tuesday, May 3, 2022, at 12:30 p.m. ET at the Westin New York Grand Central, New York, N.Y.

Plus Therapeutics to Present at the 2022 Q2 Investor Summit

First patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186 RNL for leptomeningeal metastases

Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

AUSTIN, Texas, April 19, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it will discuss new data in an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, being held June 11-14, 2022, in Vancouver, British Columbia, Canada.

Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting

AUSTIN, Texas, April 14, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report first quarter 2022 financial results on Thursday, April, 21, 2022, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.

Plus Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on April 21, 2022

AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the company will present a poster at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting, which is being held April 8-13, 2022, in New Orleans, La., and virtually.

Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Companies collaborate to design innovative registrational trial of 186 RNL for recurrent glioblastoma

Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership

AUSTIN, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will sponsor and present an industry satellite symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Therapeutics Conference, being held in-person March 10-12, 2022 at the Hyatt Regency, New Orleans, Louisiana.

Plus Therapeutics Announces Upcoming Participation at the 2022 SNMMI Therapeutics Conference

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2021 Results - Earnings Call Transcript

Initial plan to evaluate project feasibility, may lead to expanded partnership for clinical and regulatory implementation Initial plan to evaluate project feasibility, may lead to expanded partnership for clinical and regulatory implementation

Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control ArmⓇ Solution to Accelerate Brain Cancer Clinical Trial

AUSTIN, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.

Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022

AUSTIN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a company overview during the BIO CEO & Investor Conference on Monday, February 14, 2022 at 1:15 p.m. ET, at the New York Marriott Marquis.

Plus Therapeutics to Present at BIO CEO & Investor Conference

AUSTIN, Texas, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will participate at two virtual conferences in January.

Plus Therapeutics to Participate in Upcoming January Conferences

Alterity Therapeutics Ltd - ADR

Freeline Therapeutics Holdings

These penny stocks climbed during premarket trading, here's why The post Hot Penny Stocks to Watch Right Now That Are Moving in Premarket appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch Right Now That Are Moving in Premarket

Plus Therapeutics, Inc (NASDAQ: PSTV) has entered into an agreement with The University of Texas Health Science Center at San Antonio for a worldwide exclusive license to develop and commercialize novel interventional therapeutics for cancer. “The future of cancer therapy is precise targeting of tumors with the most potent cancer-killing agents while minimizing damage to normal tissues,” said Plus CEO Marc H.

Plus Therapeutics Expands Investigational Oncology Drug Pipeline

Hoth Therapeutics

Immix Biopharma

Check these three biotech penny stocks out for your watchlist right now The post Best Biotech Penny Stocks to Buy Now? 3 to Watch in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks to Buy Now? 3 to Watch in January

Plus Therapeutics Inc (NASDAQ: PSTV) has met two significant milestones as it progresses toward cGMP manufacture of Rhenium-186 NanoLiposome (186RNL). The Company has entered into a master services agreement (MSA) with IsoTherapeutics Group LLC to develop, manufacture, and supply Rhenium-186 isotope for its 186RNL investigational radiotherapeutic.

Plus Therapeutics Shares Shine After Two Milestones To Manufacture Its Lead Radiotherapeutic

AUSTIN, Texas, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a company overview during the MedInvest Oncology Investor Conference on Tuesday, December 7th at 12:00 p.m. ET.

Plus Therapeutics to Present at MedInvest Oncology Investor Conference

Plus Therapeutics Inc (NASDAQ: PSTV) released interim data from Phase 1 ReSPECT-GBM trial in patients with recurrent glioblastoma (GBM) of Rhenium-186 NanoLiposome (186RNL). According to the interim data, 186RNL delivered via convection-enhanced delivery (CED) was well-tolerated with favorable overall survival at higher absorbed radiation doses.

Plus Therapeutics' Targeted Radiotherapy Shows Encouraging Overall Survival In Brain Tumour Trial

AUSTIN, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track designation for Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM), a rare complication in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord, affecting nearly 5% of people living with cancer. The Company recently announced clearance of its Investigational New Drug (IND) application from the FDA, and expects to initiate patient accrual in the ReSPECT-LM Phase 1 dose escalation clinical trial of 186RNL in the fourth quarter of 2021.

News for Plus Therapeutics Inc Stock (PSTV)